Skip to content

Preemptive and Preventive Acetaminophen/Ibuprofen Fixed-dose Combination After Robot-assisted Radical Prostatectomy

Comparison of the Opioid-sparing Effect of Preemptive and Preventive Intravenous Acetaminophen/Ibuprofen Fixed-dose Combination After Robot-assisted Radical Prostatectomy: A Double-blind Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05685342
Enrollment
154
Registered
2023-01-17
Start date
2023-02-10
Completion date
2025-07-30
Last updated
2025-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain

Keywords

Postoperative Pain

Brief summary

This prospective, randomized, double-blinded study is designed to compare opioid-sparing effect of preemptive and preventive intravenous acetaminophen/ibuprofen fixed-dose combination in patients undergoing robot-assisted radical prostatectomy (RARP). We hypothesize that preemptive administration of intravenous acetaminophen/ibuprofen fixed-dose combination can significantly reduce postoperative opioid consumption and pain severity than preventive administration in patients undergoing RARP.

Detailed description

Adult patients undergoing elective robot-assisted radical prostatectomy are randomly allocated to receive preemptive administration of acetaminophen (1000 mg)/ibuprofen (300 mg) fixed-dose combination (n=77) or preventive administration (n=77). The preemptive administration group will receive intravenous acetaminophen (1000 mg)/ibuprofen (300 mg) for 15 minutes at the end of induction of anesthesia. The preventive administration group will receive same dosage of drug for same duration when surgical site closure starts.

Interventions

Intravenous administration of Acetaminophen (1000 mg)/Ibuprofen (300 mg) fixed-dose combination (total 100 ml)

Sponsors

Kyongbo Pharmaceutical
CollaboratorUNKNOWN
Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

An investigator who is not involved in this study randomly allocates the group and another investigator who dose not evaluate clinical endpoints keeps the result of allocation in a sealed envelope. On the day of study, the second investigator opens the envelope to check allocation and sends a drug and normal saline in identical looking bottles with label only indicating the order of administration.

Intervention model description

A prospective randomized double-blinded study

Eligibility

Sex/Gender
MALE
Age
19 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients scheduled to undergo elective robot-assisted radical prostatectomy under general anesthesia * American Society of Anesthesiologists (ASA) physical classification I-II * Consent to IV-patient controlled analgesia use * Willingness and ability to sign an informed consent document

Exclusion criteria

* Who do not understand or agree with our study * American Society of Anesthesiologists (ASA) physical classification III-IV * Chronic usage of opioid analgesics * Moderate to severe pain with other cause before surgery * Allergies to anesthetic or analgesic medications used in this study * Anticipated blood loss larger than 2 liters * Need for intensive care after surgery * History of gastric ulcer or gastrointestinal bleeding * History of liver failure, renal failure or heart failure * Current alcoholism * Taking anti-coagulation drugs or history of coagulation disease * History of bronchial asthma * Medical or psychological disease that can affect the treatment response * Taking barbitutate or tricyclic antidepressant

Design outcomes

Primary

MeasureTime frameDescription
Total fentanyl consumption during 24 hoursPostoperative 24 hoursPostoperative fentanyl consumption (mcg) via IV patient controlled analgesia

Secondary

MeasureTime frameDescription
Total fentanyl consumptionPostoperative 2, 6, 48 hoursPostoperative fentanyl consumption (mcg) via IV patient controlled analgesia (PCA)
Postoperative pain scorePostoperative 2 (resting only), 6, 24, 48 hours11-pointed NRS pain score at resting/coughing NRS (0-10): 0,no pain; 10, worst pain imaginable
Count of rescue analgesics administrationPostoperative 0-2, 2-6, 6-24, 24-48 hoursNumber of count of rescue analgesics administered because of patient's request for additional analgesia than IV PCA
Opioid side effectsPostoperative 0-2, 2-6, 6-24, 24-48 hoursIncidence of opioid side effects like postoperative nausea/vomiting, hypotension, dizziness, somnolence and respiratory depression (%)
Quality of recovery-15Postoperative 24 hoursKorean version of Quality of recovery-15 questionnaire (0-150): 0, very poor recovery; 150, excellent recovery

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026